NCT03137381

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 149 (actual)
• Sponsor: Concert Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.

Detailed description

This is a double-blind, randomized, placebo-controlled multi-center study consisting of 3 cohorts to assess the safety and efficacy of CTP-543. Each Cohort will be initiated sequentially in ascending dose order. Participants will be randomized to either an active dose of CTP-543 or placebo for a 24-week treatment period.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	CTP-543	Administered as tablets.
DRUG	CTP-543 matching placebo	Administered as tablets.

Timeline

• Start date: 2017-08-09
• Primary completion: 2019-07-08
• Completion: 2019-07-08
• First posted: 2017-05-02
• Last updated: 2022-07-19
• Results posted: 2022-07-19

Locations

13 sites across 1 country: United States

Regulatory

• FDA-regulated drug study